Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. more
Time Frame | ONCO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.38% | 0.31% | -1.26% |
1-Month Return | 43.26% | 0.6% | -4.16% |
3-Month Return | -90.3% | -9.44% | -0.46% |
6-Month Return | -89.77% | -5.15% | 3.58% |
1-Year Return | -91.35% | 0.33% | 22.47% |
3-Year Return | -99.97% | 4.53% | 25.13% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 58.47K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 573.00 | 3.06K | 4.89K | 6.75K | 1.19M | [{"date":"2019-12-31","value":0.05,"profit":true},{"date":"2020-12-31","value":0.26,"profit":true},{"date":"2021-12-31","value":0.41,"profit":true},{"date":"2022-12-31","value":0.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (573.00) | (3.06K) | (4.89K) | (6.75K) | (1.13M) | [{"date":"2019-12-31","value":-57300,"profit":false},{"date":"2020-12-31","value":-305600,"profit":false},{"date":"2021-12-31","value":-489000,"profit":false},{"date":"2022-12-31","value":-675200,"profit":false},{"date":"2023-12-31","value":-112716500,"profit":false}] |
Gross Margin | - | - | - | - | (1927.93%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-1927.93,"profit":false}] |
Operating Expenses | 879.66K | 1.62M | 3.42M | 13.48M | 34.91M | [{"date":"2019-12-31","value":2.52,"profit":true},{"date":"2020-12-31","value":4.65,"profit":true},{"date":"2021-12-31","value":9.79,"profit":true},{"date":"2022-12-31","value":38.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (880.23K) | (1.62M) | (3.42M) | (13.48M) | (36.03M) | [{"date":"2019-12-31","value":-88023000,"profit":false},{"date":"2020-12-31","value":-162206900,"profit":false},{"date":"2021-12-31","value":-341733400,"profit":false},{"date":"2022-12-31","value":-1348124000,"profit":false},{"date":"2023-12-31","value":-3603459500,"profit":false}] |
Total Non-Operating Income/Expense | - | 45.21K | (4.00) | 61.41K | (2.06M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":73.61,"profit":true},{"date":"2021-12-31","value":-0.01,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-3353.39,"profit":false}] |
Pre-Tax Income | (821.91K) | (1.60M) | (3.42M) | (13.42M) | (37.42M) | [{"date":"2019-12-31","value":-82191500,"profit":false},{"date":"2020-12-31","value":-159946600,"profit":false},{"date":"2021-12-31","value":-341733400,"profit":false},{"date":"2022-12-31","value":-1341983000,"profit":false},{"date":"2023-12-31","value":-3742228700,"profit":false}] |
Income Taxes | (3.00) | (203.24K) | (4.00) | (61.41K) | (12.59K) | [{"date":"2019-12-31","value":-300,"profit":false},{"date":"2020-12-31","value":-20324100,"profit":false},{"date":"2021-12-31","value":-400,"profit":false},{"date":"2022-12-31","value":-6141000,"profit":false},{"date":"2023-12-31","value":-1259300,"profit":false}] |
Income After Taxes | - | (1.40M) | (3.42M) | (13.36M) | (37.41M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-139622500,"profit":false},{"date":"2021-12-31","value":-341733000,"profit":false},{"date":"2022-12-31","value":-1335842000,"profit":false},{"date":"2023-12-31","value":-3740969400,"profit":false}] |
Income From Continuous Operations | - | (1.60M) | (3.42M) | (13.42M) | (37.41M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-159946600,"profit":false},{"date":"2021-12-31","value":-341733400,"profit":false},{"date":"2022-12-31","value":-1341983000,"profit":false},{"date":"2023-12-31","value":-3740969400,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (821.91K) | (1.60M) | (3.42M) | (13.42M) | (37.41M) | [{"date":"2019-12-31","value":-82191500,"profit":false},{"date":"2020-12-31","value":-159946600,"profit":false},{"date":"2021-12-31","value":-341733400,"profit":false},{"date":"2022-12-31","value":-1341983000,"profit":false},{"date":"2023-12-31","value":-3740969400,"profit":false}] |
EPS (Diluted) | - | - | (0.09) | (1.17) | (40.60) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-9,"profit":false},{"date":"2022-12-31","value":-117,"profit":false},{"date":"2023-12-31","value":-4059.71,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ONCO | |
---|---|
Cash Ratio | 0.02 |
Current Ratio | 0.06 |
Quick Ratio | 0.05 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ONCO | |
---|---|
ROA (LTM) | -21.85% |
ROE (LTM) | -1758.48% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ONCO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.34 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.55 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ONCO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 3.41 |
P/B | 0.16 |
Price/FCF | NM |
EV/R | 8.11 |
EV/Ebitda | NM |
Onconetix Inc (ONCO) share price today is $0.6017
Yes, Indians can buy shares of Onconetix Inc (ONCO) on Vested. To buy Onconetix Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ONCO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Onconetix Inc (ONCO) via the Vested app. You can start investing in Onconetix Inc (ONCO) with a minimum investment of $1.
You can invest in shares of Onconetix Inc (ONCO) via Vested in three simple steps:
The 52-week high price of Onconetix Inc (ONCO) is $18.48. The 52-week low price of Onconetix Inc (ONCO) is $0.32.
The price-to-earnings (P/E) ratio of Onconetix Inc (ONCO) is
The price-to-book (P/B) ratio of Onconetix Inc (ONCO) is 0.16
The dividend yield of Onconetix Inc (ONCO) is 0.00%
The market capitalization of Onconetix Inc (ONCO) is $4.99M
The stock symbol (or ticker) of Onconetix Inc is ONCO